Table 2 |
||||
|
Multivariable Cox proportional hazards model for time to initiation of minocycline or doxycycline |
||||
|
Hazard ratio |
95% confidence interval |
Standard error |
P value |
|
|
|
||||
|
Male sex |
1.139 |
0.887, 1.464 |
0.146 |
0.308 |
|
Age |
0.990 |
0.982, 0.998 |
0.004 |
0.021 |
|
Number of previous nonbiologic DMARDs |
1.618 |
1.532, 1.710 |
0.045 |
< 0.001 |
|
Methotrexate use |
0.728 |
0.596, 0.890 |
0.074 |
0.002 |
|
Leflunomide use |
0.622 |
0.470, 0.822 |
0.089 |
0.001 |
|
Azathioprine use |
0.378 |
0.186, 0.769 |
0.137 |
0.007 |
|
Patient Activity Score |
1.049 |
1.000, 1.100 |
0.026 |
0.051 |
|
Comorbidity index |
1.139 |
1.072, 1.210 |
0.035 |
< 0.001 |
|
Number of previous biologic DMARDs |
0.779 |
0.676, 0.898 |
0.057 |
0.001 |
|
Calendar year |
1.062 |
1.001, 1.127 |
0.032 |
0.046 |
|
|
||||
|
n = 11,987. DMARD, disease-modifying anti-rheumatic drug. |
||||
|
Smith et al. Arthritis Research & Therapy 2011 13:R168 doi:10.1186/ar3491 |
||||